These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16841374)

  • 1. Putting the colours into chromogenic in situ hybridization (CISH).
    Shipley J
    J Pathol; 2006 Sep; 210(1):1-2. PubMed ID: 16841374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.
    Laakso M; Tanner M; Isola J
    J Pathol; 2006 Sep; 210(1):3-9. PubMed ID: 16823892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
    Pedersen M; Rasmussen BB
    Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogenic in situ hybridization in tumor pathology.
    Isola J; Tanner M
    Methods Mol Med; 2004; 97():133-44. PubMed ID: 15064490
    [No Abstract]   [Full Text] [Related]  

  • 6. HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization.
    Ntoulia M; Kaklamanis L; Valavanis C; Kafousi M; Stathopoulos E; Arapantoni P; Mavroudis D; Georgoulias V; Lianidou ES
    Clin Biochem; 2006 Sep; 39(9):942-6. PubMed ID: 16916505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.
    Yan B; Choo SN; Mulyadi P; Srivastava S; Ong CW; Yong KJ; Putti T; Salto-Tellez M; Lim GS
    J Clin Pathol; 2011 Dec; 64(12):1097-101. PubMed ID: 21896578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens.
    García-Caballero T; Grabau D; Green AR; Gregory J; Schad A; Kohlwes E; Ellis IO; Watts S; Mollerup J
    Histopathology; 2010 Mar; 56(4):472-80. PubMed ID: 20459554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of c-myc amplification in formalin-fixed paraffin-embedded tumor tissue by chromogenic in situ hybridization (CISH).
    Todorović-Raković N
    Methods Mol Biol; 2013; 1012():249-54. PubMed ID: 24006070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
    Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
    J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.
    Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J
    J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromogenic In Situ Hybridization (CISH) as a Method for Detection of C-Myc Amplification in Formalin-Fixed Paraffin-Embedded Tumor Tissue: An Update.
    Todorović-Raković N
    Methods Mol Biol; 2021; 2318():313-320. PubMed ID: 34019299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dual-colour chromogenic in-situ hybridization and fluorescence in-situ hybridization in the assessment of HER2 gene amplification in breast carcinoma.
    Conlon S; Colgan A; Allen D; O'Grady A; Kay EW
    Histopathology; 2011 Jan; 58(2):319-21. PubMed ID: 21323957
    [No Abstract]   [Full Text] [Related]  

  • 15. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH).
    Fischer I; de la Cruz C; Rivera AL; Aldape K
    Diagn Mol Pathol; 2008 Dec; 17(4):227-30. PubMed ID: 18382350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.
    Gong Y; Sweet W; Duh YJ; Greenfield L; Fang Y; Zhao J; Tarco E; Symmans WF; Isola J; Sneige N
    Am J Clin Pathol; 2009 Apr; 131(4):490-7. PubMed ID: 19289584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
    Marchiò C; Natrajan R; Shiu KK; Lambros MB; Rodriguez-Pinilla SM; Tan DS; Lord CJ; Hungermann D; Fenwick K; Tamber N; Mackay A; Palacios J; Sapino A; Buerger H; Ashworth A; Reis-Filho JS
    J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue subtraction DNA in situ hybridization (TSDISH): in situ detection of DNA abnormalities in formalin-fixed paraffin-embedded tissue sections by subtraction hybridization with whole genomic DNA.
    Itakura Y; Sasano H; Mori S; Nagura H; Shimizu S
    Anticancer Res; 1997; 17(1A):121-8. PubMed ID: 9066641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
    Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
    Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.